 "Strides Arcolab Q2 net profit at Rs 2.15 cr")
Drug firm Strides Arcolab today reported a net profit of Rs 2.15 crore for the quarter ended June 30, 2013.
The company had posted a net loss of Rs 19.90 crore for the corresponding quarter previous fiscal, Strides Arcolab said in a statement.
Net sales of the company however stood at Rs 150.83 crore for the quarter under consideration as against Rs 162.65 crore for the same period year ago.
Also Read
Commenting on the results, Strides Arcolab Vice Chairman and Group CEO Arun Kumar said, "We are pleased with our performance which is in line with our guided EBITDA and Revenues."
With recent product approvals, the company expects to deliver a strong second half in the pharmaceutical business, he added.
The company currently has 46 filings with US Food and Drug Administration and has received WHO pre-qualification for Artemether and Lumifantrine (AL).
It also expects 2-3 key approvals during the second half of 2013, Strides Arcolab said.
Shares of Strides Arcolab were today trading at Rs 712.85 per scrip in the after noon trade on BSE, down 2.87% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%